TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25164220
Drug: Upfront combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront combination therapy (iloprost: 10 µg/inhalation, 6 times per day combined with oral tadalafil (5 mg) for 12 months, n = 36)
Study: 22613154
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) + Ketorolac
Study: 18544952
Drug: PEG‐IFNalpha‐2a monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNalpha‐2a monotherapy
Study: 15780524
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (free-treatment)
Study: 10333139
Drug: HBY 097
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBY 097 (non-nucleoside inhibitor of HIV-1 reverse transcriptase)
Study: 1909603
Drug: Dihydroergokryptine 10
Normalized name: α-dihydroergocryptine
DrugBank: Dihydro-alpha-ergocryptine (DB11274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergokryptine 10 mg b.i.d.
Study: 1909603
Drug: Dihydroergotamine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine 5 mg b.i.d. (controlled release)
Study: 6238741
Drug: New traction
Approvals — FDA: no, EMA: no, PMDA: no
Description: New traction treatment called auto‐traction
Study: 6238741
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of Colles' fracture with electromagnetic fields
Study: 30498836
Drug: Standard primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard primary healthcare treatment
Study: 27824811
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg b.i.d. (capsules)
Study: 25282564
Drug: Moisturizer applied
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizer applied daily during the first 32 weeks of life
Study: 21803547
Drug: Inhaled corticosteroid/bronchodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid/bronchodilator therapy (continuing treatment)
Study: 16390805
Drug: Phenobarbital 20
Normalized name: phenobarbital 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 20 mg/kg IV
Study: 9585793
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (200 ml double-strength, three times a day for 2 days)
Study: 7658286
Drug: Beta-carotene supplementation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation, large doses (exact dosage not specified)
Study: 2670423
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg norethindrone and 0.035 mg ethinyl estradiol (NET + EE)
Study: 2670423
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg norgestrel and 0.03 mg ethinyl estradiol (Ng + EE)
Study: 31345107
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg/d, n=31)
Study: 31345107
Drug: Perindopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (5 mg/d, n=31)
Study: 25746727
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 12 weeks after each dialysis session.
Study: 23176986
Drug: sufentanil 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil 5.0 μg
Study: 23176986
Drug: morphine 100
Normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 100 μg
Study: 23176986
Drug: clonidine 75
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clonidine 75 μg
Study: 18720713
Drug: Antidepressant coaxil
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant coaxil during perioperative period (6 weeks)
Study: 18720713
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no coaxil treatment)
Study: 16505759
Drug: Repeated large
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated large volume paracentesis plus intravenous albumin (group 1)
Study: 16505759
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clonidine (0.075 mg twice daily) and spironolactone (200 to 400 mg daily) (group 2)
Study: 16505759
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clonidine and spironolactone (group 2)
Study: 15198841
Drug: Weekly fructosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly fructosamine testing (Group 1)
Study: 12450445
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care of daily glucose (Group 2)
Study: 7795502
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alcohol (80 mg/100 ml)
Study: 7795502
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alcohol (40 mg/100 ml)
Study: 7795502
Drug: Expecting alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Expecting alcohol with high dose alcohol
Study: 7025168
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg body weight as a single dose
Study: 7025168
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg as a single dose
Study: 7025168
Drug: 25 mg/kg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg, twice a day at a 6-hour interval
Study: 26243373
Drug: Anti-tuberculosis therapy
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis therapy plus Silybum marianum capsule
Study: 26243373
Drug: Anti-tuberculosis therapy
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis therapy plus vitamin C tablet
Study: 24576517
Drug: Extended administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended administration of oral betrixaban (35‐42 days)
Study: 24576517
Drug: Standard short
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard short course of prophylaxis with subcutaneous enoxaparin (10 ± 4 days followed by placebo)
Study: 22510506
Drug: Feiji Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feiji Decoction for soothing the liver combined with psychotherapy and chemotherapy
Study: 18400357
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day (RG)
Study: 10575655
Drug: Etomoxir (ETO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomoxir (ETO) 75 mg
Study: 10575655
Drug: Etomoxir (ETO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomoxir (ETO) 150 mg
Study: 8688226
Drug: Concurrent external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent external radiation therapy (70 Gy/39 fractions/8 weeks) and chemotherapy with cisplatin (50 mg/m2 in short infusion, D1, D15, D29, D43) and fluorouracil (5 mg/kg, intra-muscular, every Monday, Wednesday and Friday)
Study: 8688226
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (non responders to induction chemotherapy)
Study: 8688226
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non responders to induction chemotherapy)
Study: 8688226
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (responders to induction chemotherapy)
Study: 8688226
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (responders to induction chemotherapy)
Study: 1770421
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Dentifrice with 0.075% sanguinaria extract and 2.0% zinc chloride, plus oral rinse with 0.03% sanguinaria extract and 0.2% zinc chloride.
Study: 1770421
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: Dentifrice with 0.8% sodium monofluorophosphate, 0.075% sanguinaria extract, and 0.05% zinc chloride, plus oral rinse with 0.03% sanguinaria extract and 0.2% zinc chloride.
Study: 15808922
Drug: Intravenous (iv)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (iv) ghrelin administration (1.0 microg/kg) in bulimia nervosa (BW)
Study: 15808922
Drug: Intravenous (iv)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (iv) ghrelin administration (1.0 microg/kg) in healthy women (HW)
Study: 2254718
Drug: Normal milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal milk (1180 mg Ca2+, 1650 mg K+, 110 mg Mg2+ d‐1)
Study: 2254718
Drug: Mineral-poor milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral-poor milk (95 mg Ca2+, 580 mg K+, 10 mg Mg2+ d‐1)
Study: 27750388
Drug: Commercial phage
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial phage preparation (Coliproteus from Microgen/Russia)
Study: 27750388
Drug: Coliphage preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coliphage preparations or placebo
Study: 21786113
Drug: Silymarin-based cream
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin-based cream (Leviaderm(®))
Study: 17588273
Drug: Manual-controlled infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual-controlled infusion of propofol
Study: 11229823
Drug: Antithrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin III supplementation (50 U/kg) by intravenous infusion prior to incision
Study: 9893913
Drug: Nefopam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (0.15 mg/kg)
Study: 2691569
Drug: rIFN‐alpha 2c,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐alpha 2c, 10 MU/m2 body surface, twice weekly, intramuscularly for 6 months
Study: 1090684
Drug: 2% micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% micronized griseofulvin applied 3 times daily for 3 weeks
Study: 28549145
Drug: High-dose rVSVΔG‐ZEBOV‐GP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rVSVΔG‐ZEBOV‐GP (1 × 10^8 pfu, n = 264)
Study: 21550589
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (CBT) consisting of 6 sessions combining behavioural sleep medicine techniques and anxiety treatment techniques
Study: 19687350
Drug: Amlodipine/benazepril (5.0/20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/benazepril (5.0/20.0 mg, 5.0/40.0 mg, 10.0/40.0 mg)
Study: 19687350
Drug: Hydrochlorothiazide/benazepril (12.5/20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide/benazepril (12.5/20.0 mg, 12.5/40.0 mg, 25.0/40.0 mg)
Study: 16971360
Drug: Tazarotene plus
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene plus hydroquinone (4% cream)
Study: 16971360
Drug: Tazarotene alone
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene alone (0.1% cream)
Study: 14755009
Drug: Consolidation/maintenance therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation/maintenance therapy
Study: 8325766
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of the first seizure
Study: 8325766
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of recurrences
Study: 28871492
Drug: Antibiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics + Probiotics (Lactobacillus rhamnosus GG)
Study: 28871492
Drug: Only Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only Antibiotics
Study: 28871492
Drug: Antibiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics + Placebo (glucose solution at 5%)
Study: 28361113
Drug: Standard bodyweight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bodyweight-based tacrolimus starting dose
Study: 28361113
Drug: CYP3A5 genotype-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A5 genotype-based tacrolimus starting dose
Study: 26653236
Drug: Internal medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal medicine (control)
Study: 20925972
Drug: Sequential low-frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential low-frequency right-sided followed by high-frequency left-sided rTMS
Study: 20925972
Drug: Sequential low-frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential low-frequency rTMS to both hemispheres
Study: 16598468
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.05 mg/ml) applied topically to the filtering bleb for 5 min on the 3 days after surgery
Study: 2866932
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 mg) with Hydrochlorothiazide (50 mg)
Study: 2866932
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Atenolol + Amiloride + Hydrochlorothiazide)
Study: 2866932
Drug: Diuretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic treatment alone or in combination
Study: 30347072
Drug: SDD (mouthpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDD (mouthpaste and gastrointestinal suspension with the same antibiotics)
Study: 20146685
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary interventions (PCI) with drug eluting stents (DES)
Study: 1994402
Drug: High-dose urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose urokinase (250,000 U/h for 4 hours and then 125,000 U/h)
Study: 1994402
Drug: Low-dose urokinase
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose urokinase (50,000 U/h)
Study: 1994402
Drug: High-dose urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose urokinase
Study: 1994402
Drug: Low-dose urokinase
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose urokinase
Study: 25828951
Drug: Three narrow
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three narrow diameter implants placed using osteotomes with a one-stage procedure and 12-week loading.
Study: 20106646
Drug: EPA/DHA (3.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA/DHA (3.4 g/d)
Study: 17295758
Drug: Prokinetic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetic agents (metoclopramide, domperidone, trimebutine, cisapride, itopride, mosapride)
Study: 16086935
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 IU) and Vitamin C (1000 mg) daily
Study: 16086935
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg) only
Study: 12065207
Drug: High-dose candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose candesartan (16 mg)
Study: 12065207
Drug: Low-dose candesartan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose candesartan (8 mg)
Study: 12065207
Drug: Standardised medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised medication
Study: 10049410
Drug: Endoscope insertion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscope insertion by oral route
Study: 8786163
Drug: Phyllanthus amarus
Normalized name: Phyllanthus amarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus amarus preparation for 10 days
Study: 28276566
Drug: Warfarin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (high risk)
Study: 25964594
Drug: 3D conformal
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D conformal radiotherapy (3DCRT) with hormonal therapy (HT) administered in 92% of patients
Study: 10581657
Drug: FP 4
Normalized name: PEANUT ALLERGEN-DNFP 40MG (LEVEL 5) POWDER,ORAL,PKT,30
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 4 mg
Study: 10581657
Drug: FP 1
Normalized name: Peanut Allergen-dnfp 1 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 1 mg
Study: 8694380
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (nitrous oxide and oxygen administered)
Study: 1812903
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine solution (1 mL) irrigation
Study: 6682323
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg carteolol p.o.
Study: 6682323
Drug: 1, 2,
Normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2, 5 or 25 mg carteolol
Study: 6682323
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg carteolol
Study: 6682323
Drug: 5 to
Normalized name: Hy5 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 to 25 mg carteolol
Study: 24923300
Drug: WHO Package
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHO Package of CV risk assessment, patient education, initiation and titration of antihypertensive medications, behavioral counseling on lifestyle behaviors, and medication adherence every three months for 12 months.
Study: 15703368
Drug: High-dose oxymorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxymorphone ER (3 x 20 mg q12h) + naltrexone (50 mg q24h)
Study: 15703368
Drug: Low-dose oxymorphone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxymorphone ER (10-20 mg q12h)
Study: 15703368
Drug: Rifampin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (2 x 300 mg q24h)
Study: 15703368
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg q24h)
Study: 12369078
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for acute myocardial infarction
Study: 10064246
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg/d for 12 months)
Study: 10064246
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg/d for 12 months)
Study: 6105519
Drug: Prednisone 20
Normalized name: prednisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 20 mg daily
Study: 6622929
Drug: Azathioprine 100
Normalized name: azathioprine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 100 mg daily
Study: 6105519
Drug: Prednisone 20
Normalized name: prednisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 20 mg and azathioprine 50 mg daily
Study: 6105519
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins 2 tablets daily
Study: 29691625
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 20181334
Drug: Brief information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief information about pre-endoscopy preparation (control group)
Study: 12091194
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with lithium and adjunctive psychotherapy specific to bipolar disorder
Study: 12091194
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with lithium and nonspecific intensive clinical management
Study: 8942490
Drug: Standard-dose triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose triptorelin for 8 weeks followed by reduced-dose triptorelin (100, 20, or 5 micrograms) until week 26
Study: 8942490
Drug: Reduced-dose triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose triptorelin (100, 20, or 5 micrograms)
Study: 8942490
Drug: High-dose triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose triptorelin
Study: 8942490
Drug: Reduced-dose triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose triptorelin
Study: 1959366
Drug: Pharmacokinetic dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic dosing of aminoglycosides
Study: 25193506
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day ranitidine
Study: 25193506
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day ranitidine
Study: 20874458
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol (MF/F) 200/10 μg
Study: 20874458
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/S) 250/50 μg
Study: 20874458
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol (MF/F) 400/10 μg